Healthcare · Industry
Biotechnology - List & Prices (656 stocks)
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Precigen, Inc. | PGEN | $7.10 | $2.54B | — | |
| Nektar Therapeutics | NKTR | $74.19 | $2.53B | — | |
| Mineralys Therapeutics, Inc. | MLYS | $28.21 | $2.49B | — | |
| Pharvaris N.V. | PHVS | $35.25 | $2.47B | — | |
| Harmony Biosciences Holdings, Inc. | HRMY | $42.25 | $2.46B | 13.7 | — |
| Trevi Therapeutics, Inc. | TRVI | $17.26 | $2.46B | — | |
| Nuvation Bio Inc. | NUVB | $6.81 | $2.39B | — | |
| Sarepta Therapeutics, Inc. | SRPT | $22.50 | $2.38B | — | |
| Biohaven Ltd. | BHVN | $15.69 | $2.37B | — | |
| Ocular Therapeutix, Inc. | OCUL | $10.64 | $2.34B | — | |
| Palvella Therapeutics, Inc. | PVLA | $157.24 | $2.27B | — | |
| Mesoblast Limited | MESO | $17.32 | $2.25B | — | |
| Day One Biopharmaceuticals, Inc. | DAWN | $21.53 Apr 24, 2026 | $2.22B | — | |
| Kodiak Sciences Inc. | KOD | $35.36 | $2.22B | — | |
| Rapport Therapeutics, Inc. | RAPP | $45.77 | $2.20B | — | |
| UroGen Pharma Ltd. | URGN | $44.09 | $2.16B | — | |
| ADMA Biologics, Inc. | ADMA | $9.62 | $2.15B | 13.7 | — |
| Zenas BioPharma, Inc. | ZBIO | $32.88 | $2.14B | — | |
| Aurinia Pharmaceuticals Inc. | AUPH | $16.08 | $2.14B | 7.1 | — |
| Kailera Therapeutics, Inc. | KLRA | $16.23 | $2.10B | — | |
| Generate Biomedicines, Inc. | GENB | $16.39 | $2.10B | — | |
| Zymeworks Inc. | ZYME | $29.19 | $2.09B | — | |
| Hemab Therapeutics Holdings, Inc. | COAG | $44.41 | $2.07B | — | |
| Vericel Corporation | VCEL | $40.19 | $2.06B | 83.7 | — |
| Xencor, Inc. | XNCR | $26.61 | $1.98B | — | |
| Agios Pharmaceuticals, Inc. | AGIO | $33.10 | $1.98B | — | |
| Nanobiotix S.A. | NBTX | $38.80 | $1.97B | — | |
| Kardigan, Inc. | KARD | $20.85 | $1.95B | — | |
| Recursion Pharmaceuticals, Inc. | RXRX | $3.63 | $1.95B | — | |
| GH Research PLC | GHRS | $28.23 | $1.94B | — | |
| Vir Biotechnology, Inc. | VIR | $11.39 | $1.93B | — | |
| Stoke Therapeutics, Inc. | STOK | $29.81 | $1.92B | — | |
| Braveheart Bio, Inc. | BRVE | $26.74 | $1.89B | — | |
| Lakefront Biotherapeutics NV | LKFT | $28.49 | $1.87B | 2.8 | — |
| Immunocore Holdings plc | IMCR | $36.13 | $1.86B | — | |
| Damora Therapeutics, Inc. | DMRA | $30.06 | $1.86B | — | |
| Syndax Pharmaceuticals, Inc. | SNDX | $20.56 | $1.84B | — | |
| Taysha Gene Therapies, Inc. | TSHA | $5.60 | $1.82B | — | |
| Intellia Therapeutics, Inc. | NTLA | $12.74 | $1.79B | — | |
| Inhibrx Biosciences, Inc. | INBX | $121.17 | $1.78B | — | |
| Septerna, Inc. | SEPN | $36.75 | $1.72B | — | |
| Tyra Biosciences, Inc. | TYRA | $28.65 | $1.71B | — | |
| Novavax, Inc. | NVAX | $10.22 | $1.69B | — | |
| Fortrea Holdings Inc. | FTRE | $17.70 | $1.68B | — | |
| AnaptysBio, Inc. | ANAB | $56.80 | $1.68B | — | |
| RAPT Therapeutics Inc | RAPT | $58.01 Mar 6, 2026 | $1.68B | — | |
| Avalyn Pharma Inc. | AVLN | $37.39 | $1.66B | — | |
| Ascentage Pharma Group Internat | AAPG | $17.62 | $1.65B | — | |
| Forte Biosciences, Inc. | FBRX | $76.99 Aug 28, 2026 | $1.63B | — | |
| SL Science Holding Limited | SLBT | $2.88 | $1.61B | — |
Precigen, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.54B
- P/E
- unprofitable
Nektar Therapeutics
Healthcare / Biotechnology
- Market Cap
- $2.53B
- P/E
- unprofitable
Mineralys Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.49B
- P/E
- unprofitable
Pharvaris N.V.
Healthcare / Biotechnology
- Market Cap
- $2.47B
- P/E
- unprofitable
Harmony Biosciences Holdings, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.46B
- P/E
- 13.7
Trevi Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.46B
- P/E
- unprofitable
Nuvation Bio Inc.
Healthcare / Biotechnology
- Market Cap
- $2.39B
- P/E
- unprofitable
Sarepta Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.38B
- P/E
- unprofitable
Biohaven Ltd.
Healthcare / Biotechnology
- Market Cap
- $2.37B
- P/E
- unprofitable
Ocular Therapeutix, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.34B
- P/E
- unprofitable
Palvella Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.27B
- P/E
- unprofitable
Mesoblast Limited
Healthcare / Biotechnology
- Market Cap
- $2.25B
- P/E
- unprofitable
Day One Biopharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.22B
- P/E
- unprofitable
Kodiak Sciences Inc.
Healthcare / Biotechnology
- Market Cap
- $2.22B
- P/E
- unprofitable
Rapport Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.20B
- P/E
- unprofitable
UroGen Pharma Ltd.
Healthcare / Biotechnology
- Market Cap
- $2.16B
- P/E
- unprofitable
ADMA Biologics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.15B
- P/E
- 13.7
Zenas BioPharma, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.14B
- P/E
- unprofitable
Aurinia Pharmaceuticals Inc.
Healthcare / Biotechnology
- Market Cap
- $2.14B
- P/E
- 7.1
Kailera Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.10B
- P/E
- unprofitable
Generate Biomedicines, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.10B
- P/E
- unprofitable
Zymeworks Inc.
Healthcare / Biotechnology
- Market Cap
- $2.09B
- P/E
- unprofitable
Hemab Therapeutics Holdings, Inc.
Healthcare / Biotechnology
- Market Cap
- $2.07B
- P/E
- unprofitable
Vericel Corporation
Healthcare / Biotechnology
- Market Cap
- $2.06B
- P/E
- 83.7
Xencor, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.98B
- P/E
- unprofitable
Agios Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.98B
- P/E
- unprofitable
Nanobiotix S.A.
Healthcare / Biotechnology
- Market Cap
- $1.97B
- P/E
- unprofitable
Kardigan, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.95B
- P/E
- unprofitable
Recursion Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.95B
- P/E
- unprofitable
GH Research PLC
Healthcare / Biotechnology
- Market Cap
- $1.94B
- P/E
- unprofitable
Vir Biotechnology, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.93B
- P/E
- unprofitable
Stoke Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.92B
- P/E
- unprofitable
Braveheart Bio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.89B
- P/E
- unprofitable
Lakefront Biotherapeutics NV
Healthcare / Biotechnology
- Market Cap
- $1.87B
- P/E
- 2.8
Immunocore Holdings plc
Healthcare / Biotechnology
- Market Cap
- $1.86B
- P/E
- unprofitable
Damora Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.86B
- P/E
- unprofitable
Syndax Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.84B
- P/E
- unprofitable
Taysha Gene Therapies, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.82B
- P/E
- unprofitable
Intellia Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.79B
- P/E
- unprofitable
Inhibrx Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.78B
- P/E
- unprofitable
Septerna, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.72B
- P/E
- unprofitable
Tyra Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.71B
- P/E
- unprofitable
Novavax, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.69B
- P/E
- unprofitable
Fortrea Holdings Inc.
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
AnaptysBio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
RAPT Therapeutics Inc
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
Avalyn Pharma Inc.
Healthcare / Biotechnology
- Market Cap
- $1.66B
- P/E
- unprofitable
Ascentage Pharma Group Internat
Healthcare / Biotechnology
- Market Cap
- $1.65B
- P/E
- unprofitable
Forte Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.63B
- P/E
- unprofitable
SL Science Holding Limited
Healthcare / Biotechnology
- Market Cap
- $1.61B
- P/E
- unprofitable
Showing 101–150 of 656 · ranked by market capitalization
Where the trailing year was a loss, P/E appears as “unprofitable”; a dash is missing data.